"Panacea will undertake product development and will manufacture and supply the products to Apotex, while Apotex will be responsible for regulatory affairs, Hatch Waxman litigation and commercialisation activities in the territories," said the company in its filing to the exchange.
Brokerages are worried about the stocks and stress that approval of Sun Pharma-Ranbaxy deal will be key driver. They feel that this negative surprise may benefit Dr Reddy's.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.